Showing 5101-5110 of 8086 results for "".
- Scarless Wound Healing Breakthrough: Researchers Turn Myofibroblasts in Wounds into Adipocyteshttps://practicaldermatology.com/news/scarless-wound-healing-breakthrough-researchers-turn-myofibroblasts-in-wounds-into-adipocytes/2458326/Scientists can now transform myofibroblasts found in wounds into adipocytes, paving the way toward scarless healing. Researchers began this work at the Perelman School of Medicine at the University of Pennsylvania, which led to a large-scale, multi-year study in connection with the P
- Enrollment Complete in BioPharmX's Phase 2b Study of Topical Minocycline Gel for Acnehttps://practicaldermatology.com/news/enrollment-complete-in-biopharmx-phase-2b-study-of-topical-minocycline-gel/2458331/BioPharmX Corporation completed enrollment in the OPAL (tOPicAL Minocycline Gel) study, a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, dou
- Study Examines Diversity in Dermatologic Clinical Trialshttps://practicaldermatology.com/news/study-examines-diversity-in-dermatologic-clinical-trials/2458332/Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States, according to a new report publishe
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follo
- Provectus Biopharmaceuticals Terminates CEO and COOhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-terminates-ceo-and-coo/2458335/Provectus Biopharmaceuticals, Inc.'s Board of Directors unanimously voted to terminate Peter R. Culpepper, effective immediately, from all positions held with the company, including Chief Executive Officer and Chief Operating Officer, for cause in accordance with the terms of his employment a
- Points Group and Dermatology Authority Launch the Derm Toolkit: A Revolutionary Service and Product Line for Dermatology Practiceshttps://practicaldermatology.com/news/points-group-and-dermatology-authority-launch-the-derm-toolkit-a-revolutionary-service-and-product-line-for-dermatology-practices/2458346/Points Group and Dermatology Authority are excited to announce the launch of the Derm Toolkit, an online portal that provides dermatology practices with a comprehensive set of tools and services to operate more effectively and grow their practices. Over the next four months, the
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- PuraCap Rolls Out Two New Acne Productshttps://practicaldermatology.com/news/puracap-rolls-out-two-new-acne-products/2458351/PuraCap Pharmaceutical LLC is rolling out two new acne products, Eptex Controlled Release Acne Wash and Eptex Controlled Release Acne Relief Lotion. Available through healthcare professionals, the products utilize a controlled release Intelli-Tar
- CDC Study: Banning Indoor Tanning Among Minors Will Save Lives, Moneyhttps://practicaldermatology.com/news/banning-indoor-tanning-among-minors-will-save-lives-money/2458354/An age restriction on indoor tanning could save thousands of lives and millions of dollars, according to new research published online in the Journal of the American Academy of Dermatology. In December 2015, the U.S. Food and Drug Administration
- Patient Enrollment Complete in Phase 3 Acne Trials for Minocycline Foam FMX101https://practicaldermatology.com/news/patient-enrollment-complete-in-phase-3-acne-trials-for-minocycline-foam-fmx101/2458357/Patient enrollment is now complete for two Phase 3 clinical trials evaluating the efficacy and safety of FMX101, a topical 4 percent minocycline foam for the treatment of moderate-to-severe acne, according to Foamix Pharmaceuticals Ltd. Foamix is con